The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Emerging findings in the Cancer Research UK stratified medicine program.
Emily Shaw
No relevant relationships to disclose
Alice Tuff
No relevant relationships to disclose
Rowena Sharpe
No relevant relationships to disclose
Louise K. Jones
No relevant relationships to disclose
Tarita Turtiaien
No relevant relationships to disclose
Michael Griffiths
No relevant relationships to disclose
Rachel Butler
No relevant relationships to disclose
David Gonzalez de Castro
Consultant or Advisory Role - AstraZeneca; GlaxoSmithKline; Roche
Honoraria - AstraZeneca; GlaxoSmithKline; Roche
Malcolm David Mason
No relevant relationships to disclose
V. Peter Collins
No relevant relationships to disclose
Frances Rae
No relevant relationships to disclose
T.R. Jeffry Evans
No relevant relationships to disclose
Stephen R. D. Johnston
No relevant relationships to disclose
Jane Rogan
No relevant relationships to disclose
Andrew Hanby
Consultant or Advisory Role - Roche
Honoraria - Roche
James Peach
No relevant relationships to disclose
Peter W. M. Johnson
Honoraria - Pfizer; Roche